This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gent, M. Articles by Turpie, A. G. Search for Related Content PubMed PubMed Citation Articles by Gent, M. Articles by Turpie, A. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Stroke, Vol 19, 1203-1210, Copyright © 1988 by American Heart Association

ARTICLES

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results

M Gent, JA Blakely, JD Easton, DJ Ellis, VC Hachinski, JW Harbison, E Panak, RS Roberts, J Sicurella and AG Turpie
Faculty of Health Sciences, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.

The Canadian American Ticlopidine Study is a randomized, placebo- controlled, double-blind, multicenter study to assess the efficacy and safety of ticlopidine hydrochloride in patients who have suffered a thromboembolic stroke no less than 1 week and no more than 4 months before entry into the study. The primary assessment of efficacy will be based on the cluster of outcome events recurrent stroke, myocardial infarction, or vascular death. Twenty-five clinical centers, 12 in Canada and 13 in the United States, entered a total of 1,072 patients during a 3-year recruitment period; these patients were randomly allocated to receive either 250 mg ticlopidine or identical-appearing placebo tablets twice daily for up to 3 years. Patient recruitment was completed in December 1986. Patients were followed for a maximum of 3 years or until the close of the study in December 1987; at that time an average follow-up of 25 months had been achieved. We summarize the protocol and organization of the study and document the methods of execution and analysis, with corresponding criteria, before disclosure of the treatment code to any of the study investigators. We also provide a clinical description of the patients at entry into the study.

This article has been cited by other articles:

				S. A. Grover, L. Coupal, S. Paquet, and H. Zowall Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease: Forecasting the Incremental Benefits of Preventing Coronary and Cerebrovascular Events Arch Intern Med, March 22, 1999; 159(6): 593 - 600. [Abstract] [Full Text] [PDF]

				T. Pohjasvaara, A. Leppavuori, I. Siira, R. Vataja, M. Kaste, and T. Erkinjuntti Frequency and Clinical Determinants of Poststroke Depression Stroke, November 1, 1998; 29(11): 2311 - 2317. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]

				T. Pohjasvaara, T. Erkinjuntti, R. Vataja, and M. Kaste Comparison of Stroke Features and Disability in Daily Life in Patients With Ischemic Stroke Aged 55 to 70 and 71 to 85 Years Stroke, April 1, 1997; 28(4): 729 - 735. [Abstract] [Full Text]

				T. Pohjasvaara, T. Erkinjuntti, R. Vataja, and M. Kaste Dementia Three Months After Stroke : Baseline Frequency and Effect of Different Definitions of Dementia in the Helsinki Stroke Aging Memory Study (SAM) Cohort Stroke, April 1, 1997; 28(4): 785 - 792. [Abstract] [Full Text]

				K. Li, N. Futrell, J. S. Tovar, L. C. Wang, D. Z. Wang DO, and L. R. Schultz Gender Influences the Magnitude of the Inflammatory Response Within Embolic Cerebral Infarcts in Young Rats Stroke, March 1, 1996; 27(3): 498 - 503. [Abstract] [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]